NASDAQ:CBLI
Delisted
Cleveland BioLabs Stock News
$0.240
+0.0060 (+2.56%)
At Close: May 27, 2022
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
11:22am, Monday, 16'th Aug 2021
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
07:30am, Monday, 16'th Aug 2021
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that ind
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
07:30am, Wednesday, 11'th Aug 2021
FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and hom
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
07:30am, Tuesday, 10'th Aug 2021
FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and ho
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
07:30am, Monday, 09'th Aug 2021
FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and h
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
07:33am, Thursday, 05'th Aug 2021
FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeo
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
07:33am, Thursday, 29'th Jul 2021
FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
09:16am, Tuesday, 06'th Jul 2021
FORT COLLINS, Colo. and BUFFALO, N.Y.
CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
05:58am, Friday, 18'th Jun 2021
The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.
FORT COLLINS, Colo. and BUFFALO, N.Y.
Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532
08:00am, Wednesday, 14'th Apr 2021
The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Ge
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations
03:31pm, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
CBLI Stock Price Increases Over 60% Pre-Market: Why It Happened
05:22am, Thursday, 18'th Feb 2021
The stock price of Cleveland BioLabs, Inc. (NASDAQ: CBLI) is trading at over 60% pre-market. This is why it happened.
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - CBLI, IPHI, CBMG, WTRE, CIT
08:07pm, Monday, 28'th Dec 2020
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cleveland BioLabs, Inc. (NASDAQ: CBLI) concerning po
Neutropenia Pipeline Monitor, 2020: Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com
12:00am, Monday, 03'rd Aug 2020
The
